Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medixa is an Italian aesthetic medicine company specializing in the development and production of advanced biorevitalizers and skin boosters. Its flagship product line, Hyamino, includes the 'Care 125' formulation, which combines high-concentration non-crosslinked hyaluronic acid with a synergistic complex of four essential amino acids (glycine, proline, lysine, and hydroxyproline). These products are designed to stimulate the extracellular matrix and promote natural collagen and elastin synthesis to treat deep wrinkles and skin aging. Medixa operates globally, distributing its professional-grade injectable solutions to aesthetic clinics and dermatology practices.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Care 125.